Kidney function may affect hepatitis b drug levels

NCT ID NCT07168356

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bepirovirsen

What this could lead to

If successful, this study could help doctors determine the right dose of bepirovirsen for hepatitis B patients with kidney problems.

What could go wrong

This is a very early, small study (32 people) focused on drug levels, not on treating hepatitis B. It may not lead to any treatment changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease hepatitis B virus infection kidney disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GSK Investigational Site

    Orlando, Florida, 32809, United States

  • GSK Investigational Site

    Tampa, Florida, 33603, United States

  • GSK Investigational Site

    San Antonio, Texas, 78215, United States